


HOLOGIC

Fibroid Classification Guide

COMMON FIBROID TREATMENTS


Listed from least to most invasive, including typical recovery times



The recovery times listed are not from a single source comparing recovery times. The data listed comes from a variety of sources including clinical studies and recovery guidance provided by major medical institutions.

*Most patients return to work in 4-5 days

FIBROID TARGETING - A PHYSICIAN'S PERSPECTIVE




Location		Type		Treatment
OTHER	Submucosal	0	Pedunculated intracavity	MyoSure
		1	< 50% intramural	MyoSure
		2	≤ 50% intramural	MyoSure or Sonata
OTHER	Intramural	3	Contacts endometrium; 100% intramural	Sonata or Acessa
		4	Intramural	Sonata or Acessa
OTHER	Subserosal	5	Subserosal, ≥ 50% intramural	Sonata or Acessa
		6	Subserosal, < 50% intramural	Acessa
		7	Subserosal pedunculated	Acessa or Other
		8	Other (specify e.g., cervical, parasitic)	Other
HYBRID	Transmural	2-5	Two numbers are listed separated by a dash. By convention, the first refers to the relationship with the endometrium while the second refers to the relationship to the serosa. One example is below. Submucosal and subserosal, each with less than half the diameter in the endometrial and peritoneal cavities respectively.	Sonata or Acessa

This chart is based on perspectives from physician partners who offer all three procedures. It is not representative of the full spectrum of fibroids that are indicated for each procedure. For fibroids indicated for each procedure, see the respective diagrams for the MyoSure, Sonata, and Acessa procedures.

FIBROIDS INDICATED WITH THE PROCEDURES LISTED BELOW

MyoSure®

hysteroscopic myomectomy



Sonata®

transcervical fibroid ablation



Acessa®

laparoscopic fibroid ablation



References

1. "Myomectomy." Johns Hopkins Medicine. www.hopkinsmedicine.org/health/treatment-tests-and-therapies/myomectomy-hysteroscopic-laparoscopic-abdominal. Accessed 2 Dec 2025.
2. Chudnoff S, Guido R, Roy K, Levine D, Mihalov L, Garza-Leal JG. Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas. *Obstet Gynecol.* 2019;133:13-22.
3. Chudnoff SG, Berman J, Levine DJ, Harris M, Guido RS, Banks E. SG Chudnoff, et al. Outpatient Procedure for the Treatment and Relief of Symptomatic Uterine Myomas. *Obstetrics and Gynecology*, 2013;121(5):1075–82.
4. Pron G; Mocarski E;Bennett J;Vilos G;Common A;Zaidi M;Sniderman K;Asch M;Kozak R;Simons M;Tran C;Kachura J; ; "Tolerance, Hospital Stay, and Recovery after Uterine Artery Embolization for Fibroids: The Ontario Uterine Fibroid Embolization Trial." *Journal of Vascular and Interventional Radiology : JVIR*, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/4551270/. Accessed 31 Aug. 2023.
5. Professional, Cleveland Clinic medical. "Myomectomy: Purpose, Procedure, Risks, Results & Recovery." Cleveland Clinic, <https://my.clevelandclinic.org/health/treatments/15448-myomectomy>. Accessed 8 Sept. 2023.
6. Consultant, C.O., Lingman, G. and Ottosen, L. (2000), Three methods for hysterectomy: a randomised, prospective study of short term outcome. *BJOG: An International Journal of Obstetrics & Gynaecology*, 107: 1380-1385. <https://doi.org/10.1111/j.1471-0528.2000.tb11652>.

Important Safety Information

The **Acessa ProVu system** is indicated for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa ProVu system is contraindicated for patients who are not candidates for laparoscopic surgery and/or patients with a uterus adherent to pelvic tissue or viscera. The Acessa ProVu system's guidance system is not intended for diagnostic use. Please read all instructions for use of the Acessa ProVu system prior to its use. Safe and effective electrosurgery is dependent not only on equipment design but also on factors under control of the operator. Rare but serious risks include, but are not limited to, skin burns, mild interoperative bleeding, post-procedural discomfort (cramping, pelvic pain), infection, vaginal bleeding, blood loss and complications related to laparoscopy and or general anesthesia. If you or someone you know has possibly experienced a side effect when using our product please contact your physician. Insufficient data exists on which to evaluate the safety and effectiveness of the Acessa ProVu system in women who plan future pregnancy, therefore the Acessa ProVu system is not recommended for women who are planning future pregnancy.

The **MyoSure® hysteroscopic tissue removal system** is intended for hysteroscopic intrauterine procedures by trained gynecologists to resect and remove tissue including submucous myomas, endometrial polyps, and retained products of conception. It is not appropriate for patients who are or may be pregnant, or are exhibiting pelvic infection, cervical malignancies, or previously diagnosed uterine cancer.

The **Sonata system** is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Common Side Effects include bleeding, spotting, cramping, and/or discharge. There are potential risks with this treatment such as skin burn and infection. Women who are pregnant, have a pelvic infection, are known to have gynecologic cancer, or have intratubal implants for sterilization should not have this procedure.

All Rights Reserved. Hologic, Acessa, MyoSure, Sonata and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Hologic, Inc. | 250 Campus Dr., Marlborough, MA 01752 | 508 263 2900

MISC-11186 Rev. 002 | 12/2025 | © 2025 Hologic, Inc.